Deoxyribonuclease I (DNase I) is a DNA-cleaving enzyme widely used in molecular biology, cell biology, and clinical applications. It is primarily sourced from bovine pancreas or produced recombinantly. Functioning optimally at neutral pH and 37°C in the presence of magnesium (Mg²⁺) and calcium (Ca²⁺) ions, it catalyzes hydrolytic cleavage of DNA, producing oligonucleotide fragments. DNase I is essential for removing DNA contamination from RNA samples, preparing single-cell suspensions, studying chromatin accessibility, and treating diseases like cystic fibrosis.
Deoxyribonuclease I (DNase I)
| CAS No: | 9003-98-9 |
| EINECS No: | 232-667-0 |
| EC No: | 3.1.21.1 |
| Synonyms: | Bovine DNase, deoxyribonucleate endonuclease, deoxyribonucleate 5'-oligonucleotido-hydrolase, DNA endonuclease I, DNase, DNase I, pancreatic deoxyribonuclease, pancreatic DNase, thymonuclease |
Product Summary
Function
DNase I is a hydrolytic endonuclease enzyme that catalyzes the cleavage of phosphodiester bonds within the DNA backbone. Unlike exonucleases, which remove nucleotides from the ends of DNA strands, DNase I performs internal cuts at random sites along the DNA molecule. It exhibits broad substrate specificity, capable of degrading both double-stranded (dsDNA) and single-stranded DNA (ssDNA). Upon enzymatic cleavage, DNase I generates a heterogeneous mixture of short oligonucleotide fragments, each typically bearing a 5'-phosphate group and a 3'-hydroxyl group at their respective termini. These cleavage products are the result of hydrolysis between the 3' oxygen of one nucleotide and the phosphate group linking it to the 5' carbon of the next, breaking the backbone and destabilizing the DNA structure. This mechanism allows DNase I to efficiently dismantle DNA into smaller fragments, making it an essential tool for various molecular biology and clinical applications.
Mechanism of Action
DNase I functions as an endonuclease that catalyzes the enzymatic hydrolysis of DNA by cleaving the internucleotide phosphodiester bonds that connect the sugar-phosphate backbone of nucleic acids. This hydrolytic reaction breaks the covalent linkages between adjacent nucleotides, leading to the degradation of DNA into smaller fragments.
The enzymatic activity of DNase I is dependent on the presence of divalent metal ions, primarily Mg2+ and Ca2+, which are essential cofactors for proper function and structural integrity.
- Mg2+ is critical for catalytic activity. In the presence of Mg2+, DNase I exhibits its endonucleolytic function, randomly cleaving both single-stranded and double-stranded DNA at multiple internal sites. This random cleavage produces a distribution of DNA fragments of varying lengths and is useful for applications that require DNA degradation or fragmentation.
- Ca2+, on the other hand, do not significantly contribute to catalysis but instead play a key role in stabilizing the enzyme’s tertiary structure, maintaining its proper conformation and preventing autolytic degradation (self-digestion) of the enzyme.
DNase I exhibits sequence preference in its cleavage pattern, tending to hydrolyze phosphodiester bonds adjacent to pyrimidine nucleotides—specifically cytosine and thymine—more efficiently than at purine sites. However, it is still considered a relatively non-specific endonuclease due to its ability to act broadly across DNA sequences.
As a result of its activity, DNase I generates a mixture of degradation products, including mononucleotides and short oligonucleotides, typically featuring a 5’-phosphate group and a 3’-hydroxyl group at their termini.
Applications in Scientific Research
- Molecular biology
- Removal of genomic DNA from RNA preparations: One of the most common applications of DNase I is to eliminate contaminating DNA from RNA samples during RNA extraction or purification procedures. This step is essential in experiments such as reverse transcription (RT-PCR) or RNA sequencing (RNA-seq), where even trace amounts of DNA can interfere with data interpretation by introducing background noise or false positives.
- DNase I footprinting assays: DNase I is used in DNA footprinting to study protein-DNA interactions. When a DNA-binding protein is present on a DNA molecule, it protects that specific region from enzymatic cleavage. By comparing digested DNA with and without the protein, researchers can identify binding sites and regulatory elements, providing insights into gene regulation mechanisms.
- DNA fragmentation in apoptosis detection: In apoptosis studies, DNase I is used to artificially induce or detect internucleosomal DNA cleavage, a hallmark of programmed cell death. The enzyme's ability to degrade DNA into characteristic ladder patterns (as seen in gel electrophoresis) makes it a useful tool for apoptosis assays and detection of DNA fragmentation in dying cells.
- Cell biology
- Tissue dissociation for single-cell suspensions: DNase I is often used during enzymatic tissue dissociation protocols, in combination with collagenase or trypsin, to break down extracellular DNA released from dead or damaged cells. This prevents cell clumping and facilitates the preparation of homogeneous single-cell suspensions, essential for applications like flow cytometry, cell sorting, and primary cell culture.
- Marker for apoptosis detection: Endogenous DNase I plays a physiological role during apoptosis by mediating DNA degradation within the nucleus. Experimentally, sensitivity to DNase I is used as a functional indicator of chromatin accessibility and apoptotic status, particularly in immunostaining and DNA fragmentation assays.
- Gene therapy & clinical research
- Therapeutic use in cystic fibrosis (Dornase Alfa): A recombinant form of human DNase I, known as Dornase alfa (marketed as Pulmozyme), is approved for the treatment of cystic fibrosis (CF). In CF patients, thick mucus accumulates in the lungs due to high levels of extracellular DNA from dying neutrophils. Dornase alfa reduces mucus viscosity by enzymatically breaking down this DNA, thereby improving lung function and reducing infection risk.
- Potential applications in other diseases: Research continues to explore the use of DNase I in conditions such as autoimmune diseases, thrombotic disorders, and sepsis, where extracellular DNA (including neutrophil extracellular traps, or NETs) contributes to disease pathology. DNase I could help degrade harmful DNA debris and reduce inflammation.
- Chromatin and epigenetics research
- DNase I hypersensitivity assays (DHS Assays): DNase I is an essential tool for mapping open or accessible chromatin regions within the genome. These DNase I hypersensitive sites (DHSs) are typically located in gene promoters, enhancers, and other regulatory elements, and are indicative of transcriptionally active or potentially active chromatin. High-throughput sequencing of DNase I-digested chromatin (DNase-seq) has become a powerful method for epigenomic profiling and gene regulation studies.
- Chromatin structure and nucleosome positioning: By analyzing the pattern of DNase I cleavage across chromatin, researchers can gain insights into nucleosome positioning, chromatin compaction, and epigenetic modifications, which are key to understanding genome accessibility and transcriptional regulation.
Packaging & Storage
- Sources: bovine pancreas
- Available as lyophilized powder
- Store at –20 °C, protect from moisture.
References
- Chen WJ, Liao TH. 2006: Structure and function of bovine pancreatic deoxyribonuclease I, Protein Pept Lett. 13(5): 447-53.
- Suck D. 1994: DNA recognition by DNase I, J Mol Recognit. 7(2): 65-70.
- Chen CY, et al. 2002: The distinctive functions of the two structural calcium atoms in bovine pancreatic deoxyribonuclease, Protein Sci. 11(3): 659-68.
- Fujihara J, et al. 2012: Comparative biochemical properties of vertebrate deoxyribonuclease I, Comp Biochem Physiol B Biochem Mol Biol. 163(3-4): 263-73.
- Pan CQ, et al. 1998: Mutational analysis of human DNase I at the DNA binding interface: implications for DNA recognition, catalysis, and metal ion dependence, Protein Sci. 7(3): 628-36.
- Cal S, et al. 1998: Conversion of bovine pancreatic DNase I to a repair endonuclease with a high selectivity for abasic sites, EMBO J. 17(23): 7128-38.
- Parsiegla G, et al. 2012: The structure of human DNase I bound to magnesium and phosphate ions points to a catalytic mechanism common to members of the DNase I-like superfamily, Biochemistry 51(51): 10250-8.
- Okabe N, et al. 1982: The effect of guanidine hydrochloride on the conformation of bovine pancreatic DNAase I as measured with circular dichroism, Biochim Biophys Acta 700(2): 165-70.
- Perlgut LE, Hernandez V. 1972: Kinetic studies on the mechanism on Mg(II) activation of deoxyribonuclease I, Biochim Biophys Acta (BBA) – Enzymology 289(1): 169-73.
- Poulos TL, Price PA. 1972: Some effects of calcium ions on the structure of bovine pancreatic deoxyribonuclease A, J Biol Chem. 247(9): 2900-4.
- Guéroult M, et al. 2010: How cations can assist DNase I in DNA binding and hydrolysis, PLoS Comput Biol. 6(11): e1001000.
- Price PA. 1975: The essential role of Ca2+ in the activity of bovine pancreatic deoxyribonuclease, J Biol Chem. 250(6): 1981-6.
- Suck D, et al. 1984: Three-dimensional structure of bovine pancreatic DNase I at 2.5 Å resolution, EMBO J. 3(10): 2423-30.
- Worrall AF, Connolly BA. 1990: The chemical synthesis of a gene coding for bovine pancreatic DNase I and its cloning and expression in Escherichia coli, J Biol Chem. 265(35): 21889-95.
- Nishikawa A, Mizuno S. 2001: The efficiency of N-linked glycosylation of bovine DNase I depends on the Asn-Xaa-Ser/Thr sequence and the tissue of origin, Biochem J. 355(Pt 1): 245-8.
- Yasuda T, et al. 1990: Human genetically polymorphic deoxyribonuclease: purification, characterization, and multiplicity of urine deoxyribonuclease I, J Biochem. 108(3): 393-8.
- Yasutomo K, et al. 2001: Mutation of DNASE1 in people with systemic lupus erythematosus, Nat Genet. 28(4): 313-4.
- Keyel PA. 2017: DNases in health and disease, Dev Biol. 429(1): 1-11.
- Lauková L, et al. 2020: Deoxyribonucleases and their applications in biomedicine, Biomolecules 10(7): 1036.
- Pan CQ, et al. 1998: Improved potency of hyperactive and actin-resistant human DNase I variants for treatment of cystic fibrosis and systemic lupus erythematosus, J Biol Chem. 273(29): 18374-81.
- Prince WS, et al. 1998: Pharmacodynamics of recombinant human DNase I in serum, Clin Exp Immunol. 113(2): 289-96.